Sign in

Abstract

Type III interferons (IFN-{lambda}1-{lambda}4) are known to limit influenza virus infections in vivo and are non-redundant to type I interferons (IFN- and IFN-{beta}). Here, we demonstrate that IFN-{lambda} acts through mechanisms that are beyond its ability to induce JAK/STAT signaling and promotes fast cell death in epithelial cells stimulated with poly(I:C). Studying influenza A virus (IAV) and respiratory syncytial virus (RSV) infections in vitro we notice that type I interferons, when provided prior to infection, induce higher STAT1/2 activation and a stronger accumulation of proteins coded by interferon-stimulated genes, and correspondingly suppress both IAV and RSV spread more effectively than type III interferons. The knockout of the IFN-{lambda} receptor (subunit IFNLR1), compared to the knockout of the IFN-{beta} receptor (subunit IFNAR1), only slightly influences levels of STAT1/2 phosphorylation during infection with any of the viruses; However, IFNLR1 knockout results in a greater proportion of IAV-infected cells and higher viral RNA and protein levels. We showed that the ratio of dying to infected cells is lower in IFNLR1-deficient cells compared to wild-type cells, suggesting that IFN-{lambda} promotes the rapid death of IAV-infected cells and thereby limits viral spread. This effect was not observed in RSV-infected cultures, possibly due to the RSVs ability to suppress host cell death through its nonstructural proteins. Overall, our results reveal a distinct role for IFN-{lambda} in restricting viral infections by triggering rapid death of infected epithelial cells, in contrast to type I interferons, which are the main inducers of JAK/STAT-mediated expression of ISGs, that may be used by IFN-{lambda} to trigger cell death.

02 /Specification & Classification

Click any tag to browse matching papers

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.